ASCO GU 2021 Prostate Cancer VL

Impact of Concomitant Prostate Cancer Therapy of Relugolix in Men with Advanced Prostate Cancer - Daniel J. George

Details
Daniel George, MD, and Neal Shore, MD, FACS, co-investigators of the Phase III HERO Trial join Alicia Morgans, MD, MPH recapping the 2021 GU ASCO analysis that Daniel George presented on the efficacy and safety of relugolix vs leuprolide in men with advanced prostate cancer. This was a subgroup analysis assessing the impact of concomitant prostate cancer therapy on the safety and efficacy of the o...

IPATential150 Trial in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Cora Sternberg

Details
Ipatasertib is a novel oral anti-cancer agent, under investigation in prostate and breast cancers. It is an orally administered agent designed to target three isoforms of AKT (protein kinase B), in order to block the PI3 Kinase/AKT signaling pathway. This pathway is known to contribute to prostate cancer carcinogenesis and also potentially in the resistance to anti-androgen therapies. At the ESMO...

Nivolumab Plus Docetaxel for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer from CheckMate 9KD Arm B, - Karim Fizazi

Details
Karim Fizazi joins Alicia Morgans to discuss the final analysis results for Arm B of the CheckMate 9KD trial presented at the 2021 American Society of Clinical Oncology Genitourinary Cancers annual meeting (ASCO GU). CheckMate 9KD is a phase 2 trial of nivolumab (NIVO) in combination with rucaparib, docetaxel (DOCE), or enzalutamide for patients with metastatic castration-resistant prostate cancer...

Sequential Radium-223 Treatment of mCRPC That Progressed After First-Line Novel Antihormonal Therapy, A Real-World Clinical Outcomes Study - Oliver Sartor

Details
Oliver Sartor, MD joins Alicia Morgans, MD, MPH to discuss a real-world clinical outcomes study of sequential novel antihormonal therapy (abiraterone or enzalutamide) or radium-223 (Ra-223) treatment of metastatic castration-resistant prostate cancer (mCRPC) that progressed after first-line NAH. This data is taken from the real world reports in the Flatiron Registry. Dr. Sartor presented this data...

Comparing Lutetium-PSMA Vs. Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (mCRPC) - Thera-P Trial - Michael Hofman

Details
Michael Hofman joins Alicia Morgans providing updated results from the TheraP clinical trial from data reported at the 2021 ASCO GU meeting. TheraP is the first randomized trial comparing 177Lu-PSMA-617 (Lu-PSMA), a novel radioactive treatment, to the current standard-of-care chemotherapy called cabazitaxel for men with metastatic castration-resistant prostate cancer. These men had disease that ha...